Annals of Indian Academy of Neurology
  Users Online: 391 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size

Table of Contents
Year : 2013  |  Volume : 16  |  Issue : 3  |  Page : 456-457

Author's reply on Pathophysiology of migraine

Headache Group, Department of Neurology, University of California, San Francisco, CA, USA

Date of Web Publication26-Aug-2013

Correspondence Address:
Peter J Goadsby
Headache Group, Department of Neurology, UCSF Headache Center, 1701 Divisadero St, San Francisco, CA 94115
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 24101849

Rights and PermissionsRights and Permissions


How to cite this article:
Goadsby PJ. Author's reply on Pathophysiology of migraine. Ann Indian Acad Neurol 2013;16:456-7

How to cite this URL:
Goadsby PJ. Author's reply on Pathophysiology of migraine. Ann Indian Acad Neurol [serial online] 2013 [cited 2021 Mar 9];16:456-7. Available from:


Thank you for sending along correspondence with regard to a recent review. [1] I am grateful for your correspondents' interest. They make three points:

  • They comment that citation of data from regional cerebral blood-flow studies [2] to demonstrate a disconnection between migraine pain and vasodilation is insufficient. I would agree. In a wide-reaching review sometimes not all data is cited. It is clear from other work from the same group that superficial temporal artery changes are not seen in migraine triggered by sildenafil, [3] among other examples one could adduce to this point
  • With regard to magnetic resonance angiography (MRA) work that does not demonstrate any change in extracranial vessel diameter in migraine, [4] the argument regarding vessel size is somewhat circular. While it is possible smaller vessels are the generator of pain; that has not been demonstrated and directly opposes all the more recent pharmacological data. If small vessels are important why does the non-vascular ditan class work? [5],[6]
  • Your correspondent regards the claim that gepants are without vascular effects as a serious misrepresentation. As your correspondent admits olcegepant is not a vasoconstrictor. [7] The statement made was that olcegepant has no vascular action, not that it stops calcitonin gene-related peptide (CGRP) having vasodilation. Nothing about olcegepant was misrepresented. Your correspondent tendentiously pursues vasodilation with a single example, while ignoring that the gepant data sits with the entirety of the clinical trial literature, conveniently ignoring the ditan data cited above or indeed simple things, such as the data on intravenous aspirin in migraine, [8] again as a non-vascular acute treatment.

May I add on a personal note, whatever reason some may have for developing CGRP receptor antagonists, I can assure you that the first rationale was to look at CGRP release in terms neural mechanisms. [9],[10] Migraine is a brain disorder; [11] the sooner the organ of the disorder receives full focus, the nearer we come to both enhanced understanding and better therapies.

   References Top

1.Goadsby PJ. Pathophysiology of migraine. Ann Indian Acad Neurol 2012;15:S15-22.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Olesen J, Friberg L, Olsen TS, Iversen HK, Lassen NA, Andersen AR, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990;28:791-8.  Back to cited text no. 2
3.Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003;126:241-7.  Back to cited text no. 3
4.Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation: A 3T magnetic resonance angiography study. Brain 2008;131:2192-200.  Back to cited text no. 4
5.Ferrari MD, Färkkilä M, Reuter U, Pilgrim A, Davis C, Krauss M, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan: A randomised proof-of-concept trial. Cephalalgia 2010;30:1170-8.  Back to cited text no. 5
6.Färkkilä M, Diener HC, Géraud G, Láinez M, Schoenen J, Harner N, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405-13.  Back to cited text no. 6
7.Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Lesko L, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2005;25:139-47.  Back to cited text no. 7
8.Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia 1999;19:581-8.  Back to cited text no. 8
9.Edvinsson L, Ekman R, Goadsby PJ. Vasoactive peptides in the trigeminovascular system of man. Cephalalgia 1987;7:10-2.  Back to cited text no. 9
10.Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7.  Back to cited text no. 10
11.Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011;12:570-84.  Back to cited text no. 11


Print this article  Email this article


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (436 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded28    
    Comments [Add]    

Recommend this journal